Introduction
Adenoviral vectors are appealing for in vivo gene delivery because of their capacity to efficiently transduce a wide variety of cell types, including nonreplicating cells. Although adenoviral vectors are efficient, have a large capacity, and can easily be produced at high titers, they also induce an exuberant immune response that is especially problematic for human gene therapy applications in that most individuals have pre-existing immunity to adenovirus. [1] [2] [3] [4] The inherent immunogenicity of adenovirus leads to the production of neutralizing antibodies that are responsible for limiting the effectiveness of secondary administration of vector. 5, 6 The delivery of adenoviral vectors to animals by intravenous, interperitoneal, intratracheal, intraportal, or direct injection into the pancreas has resulted in the production of neutralizing antibodies that block repeat administration. [5] [6] [7] [8] [9] For adenovirus vectors to be effective in treating chronic disease, the humoral immune response needs to be circumvented. Successful repeat administration of adenovirus has been achieved with serotype switching. [10] [11] [12] Neutralizing antibodies against one adenovirus serotype do not prevent infection by another adenovirus serotype, but this approach is rather limited in that it requires multiple adenoviral vectors to be constructed. Other attempts to avoid an immunologic response include engineering the adenovirus genome and capsid to minimize the expression of viral antigens, thus limiting the host's humoral immune response. [13] [14] [15] [16] Alternatively, investigators have attempted to prevent activation of immune cells by administering immunosuppressant agents along with adenovirus vector. 8, [17] [18] [19] [20] [21] [22] Although results from these studies are encouraging, there are significant risks associated with systemic immune suppression.
Adenoviral vectors are currently being used to deliver angiogenic genes to ischemic tissue in patients suffering from peripheral vascular disease (PVD) and coronary artery disease (CAD). 23, 24 It would be of great benefit if these angiogenic vectors could be readministered as needed. Several ongoing clinical studies are utilizing the gene encoding vascular endothelial growth factor (VEGF) to promote revascularization within ischemic tissue. [23] [24] [25] [26] [27] [28] [29] [30] VEGF, also known as vascular permeability factor, is a secreted endothelial cell-specific mitogen. 31 VEGF is expressed through alternative splicing giving rise to at least five isoforms coding for proteins of 206, 189, 165, 145, and 121 amino acids. 32, 33 VEGF binds to two highly specific tyrosine kinase receptors, Flt-1 and KDR/Flk-1, found almost exclusively on endothelial cells. [34] [35] [36] Following receptor binding, endothelial cells are stimulated to proliferate and form tube-like structures, the first steps in forming new blood vessels, a process known as angiogenesis. 37, 38 Preclinical studies have demonstrated that delivery of the VEGF gene into ischemic tissue can stimulate the development of collateral arteries in animal models of peripheral and myocardial ischemia. [39] [40] [41] [42] Adenovirus-mediated gene delivery has the ability to deliver high concentrations of proteins such as VEGF to a localized area within ischemic tissue, while minimizing the risks associated with systemic administration of angiogenic factors. Studies by our group have confirmed that high levels of localized VEGF are generated within skeletal muscle upon intramuscular injection of Ad-VEGF 121. 10 , an E1/E3-deleted adenovirus encoding human VEGF 121 under the control of a CMV promoter. We show here that despite elevated levels of circulating adenovirus reactive antibody after the first administration of vector, it is still possible to generate VEGF transgene expression and protein production within skeletal muscle upon repeat administration. In addition, we investigated the efficacy following readministration of adenoviral vector in a rat hindlimb ischemia model and provide the first evidence to confirm that the levels of VEGF protein produced after repeat adenovirus administration can translate into increased revascularization efficacy. These findings have important implications for further advancing angiogenic gene therapy to treat ischemic muscle disease.
Results

VEGF protein expression in rat skeletal muscle
To document evidence of gene expression at the protein level, the amount of human VEGF protein produced after repeat AdVEGF 121.10 administration to rat skeletal muscle was determined by ELISA. Rats received either one or two injections of AdVEGF 121.10 and the tissue was harvested after 24 h, which has previously been shown to be the point of peak expression with this vector in the rat hindlimb. As shown in Figure 1 , repeat administration of AdVEGF 121.10 to rat skeletal muscle resulted in an 11-fold decrease in VEGF protein production compared to the first administration. Although the adenoviral vector showed a significant decrease in transgene expression upon repeat dosing, the second administration effectively generated nanogram quantities of VEGF protein within the muscle. Previous dose-response studies in our laboratory in a rat hindlimb ischemia model suggested that these levels of VEGF protein may be efficacious.
Administration of AdVEGF 121.10 improves revascularization efficacy
A series of experiments were performed to determine if repeat administration of vector resulted in improved efficacy over a single administration of AdVEGF 121.10 in a rat hindlimb ischemia model. In this model system, a large section of the right femoral artery is removed to produce unilateral hindlimb ischemia. Animals were allowed to recover from surgery for 1 week prior to receiving the first injection of AdVEGF 121.10 to the skeletal muscle of the right hindlimb. Animals receiving a second administration of vector were injected 2 weeks after the first injection (day 21 postsurgery), which has previously been shown to be the time of peak antibody production. 43 Four treatment groups were evaluated: vehicle control administered day 7, AdVEGF 121.10 administered day 7, AdVEGF 121.10 day 7 þ AdVEGF 121.10 day 21, AdVEGF 121.10 day 7 þ vehicle day 21. Tissue perfusion of the right (ischemic) and left (nonischemic) foot was measured simultaneously by serial laser Doppler imaging. In order to account for variables such as light and temperature, tissue perfusion was expressed as a ratio of right to left foot. Untreated, the surgically modified limb will develop some collateral vessels over time and blood flow returns to approximately 50% of the unaltered hindlimb as seen with the vehicle control shown in Figure 2 . In contrast, a single administration of Ad-VEGF 121.10 improved blood flow, generating a 25% increase over controls. Interestingly, repeat administra- Increased efficacy after administration of AdVEGF 121 LA Perrin et al tion of AdVEGF 121.10 resulted in an additional 28% (P ¼ 0.026) increase in blood flow over a single Ad-VEGF 121.10 administration and a very significant 60% (P ¼ 0.0001) increase over control rats, whereas the AdVEGF 121.10 þ vehicle-treated group was not significantly different than AdVEGF 121.10 alone.
The development of collateral vessels was evaluated by post-mortem angiography approximately 1 month after femoral artery removal and vector administration. The number of vessels in each of the surgically modified right hindlimbs was counted by placing a grid over the X-ray film and counting the number of vascular intersections within a set area. As shown in Figure 3 , all limbs treated with AdVEGF 121.10 had significant increases in vessel numbers over vehicle controls. Importantly, the AdVEGF 121.10 þ AdVEGF 121.10 -treated group had a statistically significant increase (27%, P ¼ 0.021) over a single AdVEGF 121.10 administration, whereas AdVEGF 121.10 combined with vehicle did not demonstrate a statistically significant increase in vessel numbers on the angiograms.
Histologic analysis was performed on anti-CD31-stained tissue sections to detect endothelial cells. Vessel number was determined by placing an ocular grid over each microscopic field and counting the average number of CD31-positive vessels that fell within the grid. The data are expressed as a ratio of the number of vessels to myofibers ( Figure 4 ). All AdVEGF 121.10 -treated groups had increased CD31-positive vessels compared to vehicle controls. In addition, the AdVEGF 121.10 þ AdVEGF 121.10 -treated group had the greatest total increase in vessel number, whereas there was no significant difference in the ratio of CD31-positive vessels with the AdVEGF 121.10 þ vehicle-treated group compared to Ad-VEGF 121.10 alone.
Repeat administration of low-dose versus high-dose AdVEGF 121.10
It is well known that the level of antibodies directed against adenovirus produced by a host is dependent upon the dose of vector administered. Previous reports have documented that low doses of adenoviral vectors produce a minimal antibody response in mice after the first administration to skeletal muscle. 43 Thus, a series of experiments were carried out to test whether two low doses of AdVEGF 121.10 may be more efficacious than two high doses due to a potentially lower level of circulating adenovirus-reactive antibody. A low dose of vector was defined as 1 Â 10 8 pu and a high dose was defined as 1 Â 10 10 pu. Four treatment groups were evaluated: low dose day 7, low dose day 7 þ low dose day 21, high dose day 7, and high dose day 7 þ high dose day 21. Blood flow was monitored by serial laser Doppler perfusion imaging and tissue perfusion was expressed as a ratio of right to left foot ( Figure 5 ). Repeat administration at either a low or high dose both resulted in improved tissue perfusion compared to a single administration. Interestingly, low doses of AdVEGF 121.10 resulted in similar tissue perfusion as high doses of AdVEGF 121. 10 . Repeat administration of a low dose of AdVEGF 121.10 resulted in a modest 7% increase in blood perfusion, whereas repeat administration at the high dose of AdVEGF 121.10 showed a slightly greater increase at 14% over a single high-dose administration. Although the increases in tissue perfusion did not reach statistical significance in this experiment, it should be noted that the 'n' size was smaller than in the previous experiment ( Figure 2 ). All animals receiving a second administration of AdVEGF 121.10 reproducibly generated the greatest increases in tissue perfusion and vessel numbers compared to controls.
Collateral vessel development in the hindlimbs was determined by terminal angiography (Figure 6 ). Interestingly, repeat administration of AdVEGF 121.10 at low doses showed the greatest improvement, with blood vessel numbers increasing 35% compared to repeat administration at a high dose, with only a 9% increase in blood vessel number over a single administration. Histologic analysis on anti-CD31-stained tissue sections revealed the number of CD31-positive vessels within each treatment group (Figure 7 ). Repeat administration of AdVEGF 121.10 at either low or high doses resulted in similar vessel to myofiber ratios, with increases in the number of CD31-positive blood vessels ranging from 11 to 19% for the low dose and high dose, respectively.
Adenovirus antibody response
To monitor the development of an immune response, adenovirus-reactive IgG antibody was serially monitored over time in all treatment groups ( Figure 8 ). Animals were bled on day 7 prior to receiving the first adenovirus injection and thus serve as a baseline control. A single low dose of AdVEGF 121.10 produced very little circulating antibody; however, repeat administration with a second low dose of AdVEGF 121.10 resulted in antiadenovirus IgG levels equal to that seen with high doses of Ad-VEGF 121. 10 . In contrast, a single high dose of Ad-VEGF 121.10 was sufficient to produce large amounts of adenovirus-reactive antibodies, and when it was followed by a second high dose of vector IgG levels further increased by an additional 20%. Thus, a single administration of a low dose of adenovirus may not produce a significant antibody response, but a second administration results in prominent antibody production, similar to levels seen with high doses of vector. The kinetics of the humoral immune response demonstrate that antibody responses peak by 14 days post vector administration and are maintained at or near peak levels in the following weeks.
Discussion
Adenovirus-mediated gene delivery has the potential to produce localized protein expression, avoiding the toxicity of systemic therapy. However, a major limitation of adenoviral vectors is their inherent immunogenecity that leads to the production of neutralizing antibodies that block effective repeat administration. To date, the majority of studies evaluating repeat dosing of adenoviral vectors have focused on delivery to the liver and lungs utilizing intravenous and intranasal/tracheal routes of administration. The present study evaluated repeat administration of adenoviral vector to skeletal muscle and showed that despite increased levels of circulating adenovirus-reactive antibodies, a second administration of AdVEGF 121.10 to skeletal muscle results in nanogram quantities of VEGF protein produced within the tissue. Most importantly, this study confirmed that this amount Increased efficacy after administration of AdVEGF 121 LA Perrin et al location of tissue harvest can greatly affect the outcome. In general, CD31 expression is enhanced to the greatest extent within close proximity to the AdVEGF 121.10 injection sites. However, at the time of animal killing, it was difficult to determine where the injection sites were located within the muscle. In contrast, angiography provides a clear picture of all sizeable vessels within the hindlimb. Thus, for vessel assessment, angiography may provide a more accurate representation in that the entire hindlimb is evaluated versus a small, limited area as seen with histology. Similarly, laser Doppler analysis is limited in that it is only capable of detecting flow in small vessels that are within 0.6-1.0 mm of the skin surface. The clinical significance of such small vessels in ischemic muscle is highly debated. It is hypothesized that larger, more mature vessels are required to provide significant tissue perfusion. Thus, in the current study, anigography may be the most relevant end point in that it captures larger, more mature vessels throughout the limb. Whether new, small blood vessels develop in AdVEGF 121.10 -injected muscle or whether existing blood vessels become enlarged following the second injection is unknown. However, based upon the known mechanisms of action of VEGF and our own observations, we hypothesize that it is most likely a combination of both new blood vessels being formed and enlargement or dilatation of existing vessels. Our findings indicate that it is possible to effectively readminister adenovirus to skeletal muscle. This is in contrast to a report by Massari et al, 44 who were unable to detect b-galactosidase activity following repeat intramuscular administration of an Ad-LacZ vector in rats. There are several differences between the studies that could account for the discrepancy. The two studies varied in the strain and age of rats utilized, doses, timing of injections, time points evaluated, and utilized different adenoviral vectors carrying different transgenes. In support of our findings, a study by Chen et al reported effective repeat intramuscular administration in mice utilizing an adenovirus vector similar to the one used in the current study. Utilizing C57BL/6 or Balb/c mice and similar dosing parameters, these investigators were able to demonstrate successful adenovirus readministration to skeletal muscle. 43 It should be noted that since repeat dosing of AdVEGF 121.10 improved revascularization efficacy, it suggests that prolonged VEGF expression may be required to optimally revascularize ischemic tissue. To date, it is unclear what amount of VEGF or any other angiogenic factor is required for optimal vessel formation within ischemic tissue. The fact that the low dose of AdVEGF 121.10 resulted in similar efficacy as the high dose of AdVEGF 121.10 may indicate that a threshold level of VEGF is required for revascularization, which was reached at the 1 Â 10 8 pu dose in our model. Thus, the current study implies that there may be a range of AdVEGF 121.10 doses that may be effective at enhancing revascularization, as exemplified by both the 1 Â 10 8 and 1 Â 10 10 pu being efficacious. Indeed, when delivering angiogenic factors, more may not necessarily be better but may actually be deleterious. Lee et al 45 found that strong, persistent expression of VEGF can result in lethal hemangiomas. Myoblasts transduced with a retrovirus encoding the VEGF gene generated substantial hemangiomas in the hearts of mice within 2 weeks of being transplanted. 45 The study suggested that there may be a dose-related response and that continuous exposure to high levels of VEGF may actually be detrimental owing to the excess stimulation of endothelial cells and subsequent vascular development. It should be noted that in the current study, no evidence of hemangioma formation was observed with either a single or a second administration of AdVEGF 121.10 at any of the doses evaluated.
PVD produces symptomatic disability in more than 1 million patients each year in the US, resulting in thousands of lower limb amputations. 46 Therapies that improve blood flow by stimulating the growth and development of collateral vessels show great promise for the treatment of PVD as well as for coronary artery disease which, despite significant advances in its prevention, remains the leading cause of death in the US. 47 Gene therapy trials using plasmids and adenoviral vectors to treat ischemic disease have been met with cautious optimism. Direct injection of plasmid encoding VEGF into the peripheral limbs of patients in a Phase I clinical trial demonstrated improved peripheral blood flow, new collateral vessel formation, healing of ischemic ulcers and reduced the need for amputation. [28] [29] [30] Similarly, Phase I trials evaluating plasmid-or adenovirus-mediated gene delivery of VEGF into the ischemic myocardium of patients found reductions in angina class, reduced need for anginal medication, increased number of collaterals by angiography, improvements in myocardial perfusion and increased exercise treadmill times. 23, [25] [26] [27] Although these early clinical trials have had limited patient numbers and lacked placebo controls, they have generated enthusiasm for further studies.
Repeat administration of vector will likely be required for effective treatment of chronic ischemic disease in the clinic. Thus, it would be of great benefit to be able to readminister vector as needed for recurrent disease and to aid in the further improvement of current gene therapy treatments. Our data suggest that repeat administration of adenovirus vector into muscle can be Increased efficacy after administration of AdVEGF 121 LA Perrin et al effective and results in improved efficacy. The concentration of adenovirus-specific antibodies in the muscle may be lower than that found in the serum, allowing for effective transduction even in the presence of a humoral immune response. Thus, repeat administration of adenovirus vectors to muscle may be possible without viral modifications or immune suppression. Of course, clinical studies will be necessary to confirm whether these studies are predictive for humans. Nevertheless, these findings have important implications for further increasing the effectiveness of angiogenic gene transfer in the treatment of ischemic muscle disease.
Materials and methods
Vectors
AdVEGF 121.10 is an E1a, partial E1b, partial E3-deleted replication-deficient adenovirus vector expressing VEGF 121 from the cytomegalovirus (CMV) promoter Increased efficacy after administration of AdVEGF 121 LA Perrin et al and carries the simian virus 40 poly A sequences from an expression cassette inserted at the site of the E1 deletion. Viral particle number was determined for all vectors by an optical density reading at 260 nm and the titer of each viral stock was determined by fluorescent focus assay. All virus was tested and found to have replicationcompetent adenovirus levels of less than 1 in 1 Â 10 7 PFU.
VEGF quantification
Six-month-old male Sprague-Dawley rats (Charles River Laboratories, MA, USA) were anesthetized and a small incision was made to expose the large left lateral muscle of the hindlimb. The injection site was marked with a suture and the vector administered at 2 Â 10 10 pu in a 100 ml volume in 3% sucrose vehicle. Upon killing, skeletal muscle was harvested and sectioned into slices perpendicular to the muscle striations. All tissue was rinsed in cold saline, frozen in liquid nitrogen, and stored at -801C. Tissue was pulverized into a fine powder using a freezer mill with liquid nitrogen and homogenized for ELISA analysis and total protein determination. Approximately 100 mg of frozen, pulverized tissue was solubilized in 1 ml of lysis buffer (250 mM Tris HCL, 0.5% Triton X-100, 50 mg/ml leupeptin, 100 mg/ml aprotinin and 200 mg/ml Pefabloc, pH 7.4), centrifuged for 10 min at 14 000 rpm in a microcentrifuge Increased efficacy after administration of AdVEGF 121 LA Perrin et al and the supernatant was analyzed. VEGF protein levels were quantitated using commercially available antibodies (R&D Systems, #DVE00, Minneapolis, MN, USA). Protein determinations were made for each muscle sample using the BioRad protein assay (BioRad Laboratories, Hercules, CA, USA).
Rat hindlimb ischemia model
Six-month-old male Sprague-Dawley rats (Charles River Laboratories, MA, USA) were anesthetized with a Telazol (30 mg/kg) injection into the right shoulder muscle. A vertical longitudinal incision was performed in the rat hindlimb above the inguinal ligament. The right femoral artery in the limb was dissected through the incision, ligated (including branches derived from this artery), and then cut at the point of the inguinal ligament down to the bifurcation of saphenous and popliteal arteries. The total length of femoral artery removal was approximately 25 mm. A total of 2 Â 10 8 pu (unless indicated otherwise) of AdVEGF 121.10 was injected 7 days after surgery into the following three locations in the right hindlimb: medial thigh muscle, lateral thigh muscle, and medial calf muscle. Interstitial cells are the primary cells transduced by this vector in rat skeletal muscle.
Laser Doppler perfusion imaging
Laser Doppler perfusion imaging was utilized to determine serial blood flow measurements. The laser Doppler perfusion imager (PIM II, Lisca Inc., Hewitt, NJ, USA) incorporates a helium-neon laser, generating a beam of light that sequentially scans the tissue surface to a depth of 0.6-1.0 mm. During the scanning procedure, blood cells passing through the vasculature shift the frequency of incident light according to the Doppler principle. For the rat hindlimb model, tissue perfusion of the right (ischemic) and left (non-ischemic) plantar surfaces of the foot was measured simultaneously and the average perfusion of each foot was calculated. To account for variables such as ambient light and temperature, tissue perfusion was expressed as a ratio of right to left foot perfusion.
Post-mortem angiography
Immediately following CO 2 euthanasia, a cannula was placed into the rat abdominal aorta and the lower extremities were perfused with 120 ml warm saline containing 41.7% papaverine (Sigma, MO, USA) and 200 U heparin (Elkins-Sinn Inc., NJ, USA). Saline perfusion was immediately followed by perfusion with barium-gelatin contrast for 15 min at a pressure of 120 mmHg. X-rays were taken and the number of vessels in the lower limbs was counted by placing a grid over the X-ray film and counting the number of vascular intersections within a set area.
Histology
Tissue samples were fixed in Zinc-Tris solution overnight, embedded in paraffin, and sectioned at a thickness of 5-6 mm. Sections were stained with hematoxylin and eosin for histologic analysis and with anti-CD31 (TLD-3A12, Pharmingen, CA, USA) to detect endothelial cells. Vessel numbers were determined by placing an ocular grid over each microscopic field and counting the number of vessels that fell within the grid. Five highpower fields were counted for each section and the average number of vessels was taken to represent the vessel density.
Adenovirus antibody assay
Adenovirus-reactive IgG was measured in sera of rats by ELISA. In between all ELISA steps, plates were washed with 0.05% Tween 20 in PBS. Plates were coated overnight with 100 ml of 7.5 Â 10 9 pu/ml AdNull diluted in PBS. Wells were blocked for 2 h at room temperature with 1% BSA solution. Experimental samples were diluted in 1% BSA and 100 ml was added to plates in triplicate. After a 1-h incubation, 100 ml of secondary biotinylated antibody specific for rat IgG (Zymed Laboratories, Inc.) was added to each well. Plates were incubated for 1 h. A total of 100 ml (2 mg/ml) of HRP-avidin (Sigma) was then added, and the plates were incubated at room temperature for 30 min. ABTS (100 ml) was then added to each well, and absorbance was determined at 405 nm within 15-30 min using spectrophotometer. Increased efficacy after administration of AdVEGF 121 LA Perrin et al
